Trial Outcomes & Findings for Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS) (NCT NCT02224482)

NCT ID: NCT02224482

Last Updated: 2021-10-12

Results Overview

Adaptive coping was measured with the Cancer Coping Questionnaire. The total score from the Cancer Coping Questionnaire is a mean scale. There were a total of 14 items, each with a Likert-type 4-point scale, with 1 being the minimum value and 4 being the maximum value. A higher score indicated greater coping ability (i.e., better outcome).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

431 participants

Primary outcome timeframe

Change in coping from baseline to six months

Results posted on

2021-10-12

Participant Flow

Participant milestones

Participant milestones
Measure
Control
Print materials
Intervention Group
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Overall Study
STARTED
214
217
Overall Study
COMPLETED
63
57
Overall Study
NOT COMPLETED
151
160

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Different counts due to missing data

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control
n=214 Participants
Print materials
Intervention Group
n=217 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Total
n=431 Participants
Total of all reporting groups
Age, Continuous
63.3 years
STANDARD_DEVIATION 7.5 • n=214 Participants
63.8 years
STANDARD_DEVIATION 6.7 • n=217 Participants
63.5 years
STANDARD_DEVIATION 7.1 • n=431 Participants
Sex: Female, Male
Female
0 Participants
n=214 Participants
0 Participants
n=217 Participants
0 Participants
n=431 Participants
Sex: Female, Male
Male
214 Participants
n=214 Participants
217 Participants
n=217 Participants
431 Participants
n=431 Participants
Race/Ethnicity, Customized
Non-Hispanic White
143 Participants
n=214 Participants • Different counts due to missing data
160 Participants
n=217 Participants • Different counts due to missing data
303 Participants
n=431 Participants • Different counts due to missing data
Race/Ethnicity, Customized
Black
51 Participants
n=214 Participants • Different counts due to missing data
40 Participants
n=217 Participants • Different counts due to missing data
91 Participants
n=431 Participants • Different counts due to missing data
Race/Ethnicity, Customized
Other
18 Participants
n=214 Participants • Different counts due to missing data
17 Participants
n=217 Participants • Different counts due to missing data
35 Participants
n=431 Participants • Different counts due to missing data
Race/Ethnicity, Customized
Unknown
2 Participants
n=214 Participants • Different counts due to missing data
0 Participants
n=217 Participants • Different counts due to missing data
2 Participants
n=431 Participants • Different counts due to missing data
Region of Enrollment
United States
214 participants
n=214 Participants
217 participants
n=217 Participants
431 participants
n=431 Participants
PSA at diagnosis (ng/ml)
8.6 ng/ml
STANDARD_DEVIATION 10.7 • n=214 Participants
14.0 ng/ml
STANDARD_DEVIATION 49.0 • n=217 Participants
11.4 ng/ml
STANDARD_DEVIATION 35.6 • n=431 Participants
Prostate cancer treatment completed
Surgery Only
131 Participants
n=212 Participants • Counts different due to missing data
130 Participants
n=213 Participants • Counts different due to missing data
261 Participants
n=425 Participants • Counts different due to missing data
Prostate cancer treatment completed
Radiation Only
50 Participants
n=212 Participants • Counts different due to missing data
59 Participants
n=213 Participants • Counts different due to missing data
109 Participants
n=425 Participants • Counts different due to missing data
Prostate cancer treatment completed
Other (multiple treatments)
31 Participants
n=212 Participants • Counts different due to missing data
24 Participants
n=213 Participants • Counts different due to missing data
55 Participants
n=425 Participants • Counts different due to missing data

PRIMARY outcome

Timeframe: Change in coping from baseline to six months

Population: Data provided for participants with six month data

Adaptive coping was measured with the Cancer Coping Questionnaire. The total score from the Cancer Coping Questionnaire is a mean scale. There were a total of 14 items, each with a Likert-type 4-point scale, with 1 being the minimum value and 4 being the maximum value. A higher score indicated greater coping ability (i.e., better outcome).

Outcome measures

Outcome measures
Measure
Control
n=106 Participants
Print materials
Intervention Group
n=103 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Adaptive Coping
-0.089 score on a scale
Standard Deviation 0.559
-0.013 score on a scale
Standard Deviation 0.602

SECONDARY outcome

Timeframe: Change from baseline to six months

This will be measured using the Urinary Incontinence Scale from the Expanded Prostate Cancer Index Composite - Short Form (EPIC 26-SF), a 26 item shortened version of EPIC, a 61 item questionnaire for assessing urinary, bowel, sexual, and hormonal dysfunction and distress/bother in prostate cancer patients. The scale had four items, each with a Likert-type 4- or 5-item scale, with 1 being the minimum and 4 or 5 being the maximum. These scores were then recoded to a 0 to 100 scale, with higher scores indicating less urinary incontinence (i.e., better outcome).

Outcome measures

Outcome measures
Measure
Control
n=101 Participants
Print materials
Intervention Group
n=96 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Physical Functioning - Urinary Incontinence
9.240 score on a scale
Standard Deviation 19.671
10.750 score on a scale
Standard Deviation 21.933

SECONDARY outcome

Timeframe: Change from baseline to six months

This will be measured using the Urinary Irritation Scale from the Expanded Prostate Cancer Index Composite - Short Form (EPIC 26-SF), a 26 item shortened version of EPIC, a 61 item questionnaire for assessing urinary, bowel, sexual, and hormonal dysfunction and distress/bother in prostate cancer patients. The scale had four items, each with a Likert-type 4- or 5-item scale, with 1 being the minimum and 4 or 5 being the maximum. These scores were then recoded to a 0 to 100 scale, with higher scores indicating less urinary irritation (i.e., better outcome).

Outcome measures

Outcome measures
Measure
Control
n=100 Participants
Print materials
Intervention Group
n=94 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Physical Functioning - Urinary Irritation
10.063 score on a scale
Standard Deviation 17.200
7.979 score on a scale
Standard Deviation 16.660

SECONDARY outcome

Timeframe: Change from baseline to six months

This will be measured using the Bowel Scale from the Expanded Prostate Cancer Index Composite - Short Form (EPIC 26-SF), a 26 item shortened version of EPIC, a 61 item questionnaire for assessing urinary, bowel, sexual, and hormonal dysfunction and distress/bother in prostate cancer patients. The scale had six items, each with a Likert-type 4- or 5-item scale, with 1 being the minimum and 4 or 5 being the maximum. These scores were then recoded to a 0 to 100 scale, with higher scores indicating less bowel problems (i.e., better outcome).

Outcome measures

Outcome measures
Measure
Control
n=102 Participants
Print materials
Intervention Group
n=97 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Physical Functioning - Bowel
1.479 score on a scale
Standard Deviation 13.330
3.119 score on a scale
Standard Deviation 14.847

SECONDARY outcome

Timeframe: Change from baseline to six months

This will be measured using the Sexual Functioning Scale from the Expanded Prostate Cancer Index Composite - Short Form (EPIC 26-SF), a 26 item shortened version of EPIC, a 61 item questionnaire for assessing urinary, bowel, sexual, and hormonal dysfunction and distress/bother in prostate cancer patients. The scale had six items, each with a Likert-type 4- or 5-item scale, with 1 being the minimum and 4 or 5 being the maximum. These scores were then recoded to a 0 to 100 scale, with higher scores indicating less sexual problems (i.e., better outcome).

Outcome measures

Outcome measures
Measure
Control
n=98 Participants
Print materials
Intervention Group
n=96 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Physical Functioning - Sexual Functioning
4.793 score on a scale
Standard Deviation 19.829
3.046 score on a scale
Standard Deviation 21.402

SECONDARY outcome

Timeframe: Change from baseline to six months

Satisfaction with communication in medical interactions will be assessed with the medical interactions scale from the Cancer Rehabilitation Evaluation System (CARES): difficulty communicating with the medical team, and problems obtaining information from the medical team. The minimum value is 0 and the maximum value is 4. A higher score means patients had worse medical interactions (i.e., worse outcome).

Outcome measures

Outcome measures
Measure
Control
n=103 Participants
Print materials
Intervention Group
n=96 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Interpersonal Concerns - Medical Interactions
-0.311 score on a scale
Standard Deviation 2.783
-0.531 score on a scale
Standard Deviation 2.554

SECONDARY outcome

Timeframe: Change from baseline to six months

Satisfaction with marital communication will be assessed from the marital problems scale from the Cancer Rehabilitation Evaluation System (CARES). The minimum value is 0 and the maximum value is 4. A higher score means more marital problems (i.e., worse outcome).

Outcome measures

Outcome measures
Measure
Control
n=95 Participants
Print materials
Intervention Group
n=88 Participants
PROGRESS PROGRESS: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Interpersonal Concerns - Marital Interactions
-0.042 score on a scale
Standard Deviation 3.956
0.182 score on a scale
Standard Deviation 3.358

Adverse Events

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Intervention Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Suzanne Miller

Fox Chase Cancer Center

Phone: 215-728-4069

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place